Karyopharm Therapeutics Inc (NASDAQ:KPTI) Director Mansoor Raza Mirza sold 2,500 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $17.01, for a total transaction of $42,525.00. Following the sale, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $42,525. The sale was disclosed in a filing with the SEC, which is available at this link.
Karyopharm Therapeutics Inc (NASDAQ KPTI) traded down $0.65 during trading hours on Thursday, reaching $16.16. 537,479 shares of the company’s stock traded hands, compared to its average volume of 306,399. The firm has a market cap of $842.56, a price-to-earnings ratio of -6.10 and a beta of 3.62. Karyopharm Therapeutics Inc has a 12 month low of $7.48 and a 12 month high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $2.26 million. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. The business’s revenue for the quarter was up 3163.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.65) earnings per share. analysts forecast that Karyopharm Therapeutics Inc will post -2.66 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Palo Alto Investors LLC boosted its holdings in Karyopharm Therapeutics by 1.3% in the 4th quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock valued at $34,027,000 after purchasing an additional 45,854 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Karyopharm Therapeutics by 6.4% in the 4th quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock worth $32,041,000 after acquiring an additional 200,310 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after acquiring an additional 384,658 shares during the last quarter. State Street Corp lifted its holdings in shares of Karyopharm Therapeutics by 10.1% in the 2nd quarter. State Street Corp now owns 511,920 shares of the company’s stock worth $4,631,000 after acquiring an additional 47,127 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 17.8% in the 4th quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock worth $4,194,000 after acquiring an additional 65,920 shares during the last quarter. Institutional investors own 62.60% of the company’s stock.
KPTI has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. initiated coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 price objective for the company. ValuEngine cut shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.67.
WARNING: “Karyopharm Therapeutics Inc (KPTI) Director Mansoor Raza Mirza Sells 2,500 Shares of Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/15/karyopharm-therapeutics-inc-kpti-director-mansoor-raza-mirza-sells-2500-shares-of-stock.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.